araag2/HINT huggingface dataset:
Clinical trial NCT00396409 (phase 3, status: completed)
Conditions: allergic asthma
ICD codes: D69.0, L50.0, B44.81, J30.89, J30.9, L20.84, H10.45
Drugs: depigoid, omalizumab, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males or females of any race who are 12-45 years of age with a body weight ≥ 20 kg and
             ≤ 150 kg and with a total serum IgE level ≥ 30 to ≤ 700 IU/ml (suitable weight for
             dosing)

          -  Patients with the diagnosis of not adequately controlled seasonal grass pollen (and/or
             rye pollen) and allergic asthma with concomitant seasonal allergic rhinoconjunctivitis
             within > 2 previous seasons

          -  patients with a positive RAST (>CAP2) result for grass pollen (and/or rye pollen)
             specific IgE at screening (Visit 1 (V1) or within the previous 12 months.

          -  Patients with FEV1 > 80% of the predicted normal value for the patient at screening
             [V1](demostrable at least 6 hours after last short acting B-2 agonist use or 12 hours
             after last long B-2 acting agonist use).

        Exclusion Criteria:

          -  Females of childbearing potential: pregnancy, birth control,breast-feeding

          -  Concurrent diseases/conditions and history of other diseases/conditions

               1. patients who have a positive history of significant clinical manifestations of
                  allergy as a result of sensitization against tree pollen allergens, weed
                  allergens and perennial allergens (e.g. Aspergillus spores, animal dander, house
                  dust mite).

               2. patients with a history of food or drug related severe anaphylactoid or
                  anaphylactic reaction(s).

          -  Ingredient hypersensitivity

               1. patients with known hypersensitivity to any ingredients, including excipients
                  (sucrose, histidine, polysorbate 20) of the study medication, any immunotherapy,
                  or drugs related to Omalizumab (e.g., monoclonal antibodies, polyclonal gamma
                  globulin).

               2. patients with hypersensitivity to the trail's asthma rescue- or
                  escalation-medication or related drugs.
Clinical trial NCT00625612 (phase 3, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: denufosol tetrasodium (ins37217) inhalation solution, placebo
SMILES: [H]N([H])C1=NC(=O)N(C=C1)[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)N2C=CC(=O)N([H])C2=O)O1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have confirmed diagnosis of cystic fibrosis

          -  Have FEV1 of greater than or equal to 75% but less than or equal to 110%predicted
             normal for age, gender and height

          -  Be able to reproducibly perform spirometry

          -  Be clinically stable for at least 4 weeks before screening

        Exclusion Criteria:

          -  Have abnormal renal or liver function

          -  Have lung transplant

          -  Unable to discontinue use of hypertonic saline

          -  Participated in Inspire trial 08-108
Clinical trial NCT00695643 (phase 3, status: terminated)
Conditions: diverticulitis
ICD codes: K57.00, K57.01, K57.12, K57.13, K57.20, K57.21, K57.32
Drugs: mesalazine, placebo
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of left-sided uncomplicated diverticular disease confirmed by
             ultrasonography or computed tomography

          -  Presence of at least one diverticulum of the left colon

          -  Most recent attack of left-sided uncomplicated diverticulitis responding to
             antibiotics and/or dietary modification within the last 6 months

          -  C-reactive protein (CRP) > upper limit of normal (ULN) at the start of the most recent
             attack

        Exclusion Criteria:

          -  Complicated diverticular disease

          -  Right-sided diverticulitis

          -  Previous colonic surgery

          -  Presence of symptomatic organic disease of the gastrointestinal tract

          -  Active colorectal cancer or a history of colorectal cancer

          -  Hemorrhagic diathesis

          -  Active peptic ulcer disease, local intestinal infection

          -  Asthma if careful medical monitoring is not ensured

          -  Abnormal hepatic function or liver cirrhosis

          -  Abnormal renal function
Clinical trial NCT00433290 (phase 3, status: completed)
Conditions: osteoarthritis knee pain
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female outpatients with osteoarthritis knee pain.

        Exclusion Criteria:

          -  Serious cardiovascular, hepatic, renal, respiratory, or hematologic illness, or other
             medical or psychiatric condition that, in the opinion of the investigator, would
             compromise participation or be likely to lead to hospitalization during the course of
             the study.

          -  Previous exposure to duloxetine.
Clinical trial NCT00516074 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with type 2 diabetes.

          -  Treated with metformin and/or a thiazolidinedione.

          -  HbA1c between 6.5% and 9.5%, inclusive.

          -  Body Mass Index (BMI) > 25 kg/m^2 and < 40 kg/m^2.

        Exclusion Criteria:

          -  Have previously received exenatide or glucagon-like peptide-1 analogs.

          -  Have participated in an interventional medical, surgical, or pharmaceutical study (a
             study in which an experimental, drug, medical, or surgical treatment was given) within
             30 days of screening. This criterion includes drugs that have not received regulatory
             approval for any indication at the time of study entry.

          -  Receiving beta blockers.

          -  Receiving treatment with a drug directly affecting gastrointestinal motility,
             including but not limited to Reglan® (metoclopramide), Propulsid® (cisapride), and
             chronic macrolide antibiotics.

          -  Have received treatment with systemic glucocorticoid therapy by oral, intravenous
             (IV), or intramuscular (IM) route within 6 weeks of screening, or are regularly
             treated with potent, inhaled intranasal steroids that are known to have a high rate of
             systemic absorption or bronchodilators.

          -  Have been treated with drugs that promote weight loss (for example, Adipex®
             [phentermine], Acomplia® [rimonabant], Xenical® [orlistat], Meridia® [sibutramine],
             Acutrim® [phenylpropanolamine], or similar over-the-counter medications) within 3
             months of screening.

          -  Have been treated for longer than 2 weeks with any of the following excluded
             medications within 3 months prior to screening: *Insulin; *Alpha-glucosidase
             inhibitors (for example, Glyset® [miglitol] or Precose® [acarbose]); *Meglitinides
             (for example, Prandin® [repaglinide] or Starlix® [nateglinide]); *Sulfonylureas (for
             example, Glucotrol® [glipizide] or Micronase® [glyburide]); *Dipeptidyl peptidase IV
             (DPP-IV) inhibitors (for example, Januvia™ [sitagliptin])

          -  Have donated blood within 60 days of screening.
Clinical trial NCT01309204 (phase 3, status: completed)
Conditions: open-angle glaucoma, ocular hypertension
ICD codes: H40.10X0, H40.10X1, H40.10X2, H40.10X3, H40.10X4, H40.1130, H40.1131, H40.053, H40.051, H40.052, H40.059
Drugs: brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension, vehicle, brinzolamide 1% ophthalmic suspension, brimonidine tartrate 0.2% ophthalmic solution
SMILES: CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, CC1=CC(O)=CC(C)=C1Cl, CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosed with open-angle glaucoma or ocular hypertension and, in the opinion of the
             Investigator, are insufficiently controlled on monotherapy or are currently on
             multiple IOP-lowering medications.

          -  Meet qualifying IOP entry criteria.

          -  Able to understand and sign an informed consent form.

          -  Other protocol-specified inclusion criteria may apply.

        Exclusion Criteria:

          -  Women of childbearing potential if pregnant, test positive for pregnancy at Screening
             visit, breastfeeding, or not in agreement to use adequate birth control methods to
             prevent pregnancy throughout the study.

          -  Severe central visual field loss.

          -  Can not safely undergo the initial washout period and discontinue use of all
             IOP-lowering ocular medication(s) for the minimum specified period prior to
             Eligibility Visit 1.

          -  Best corrected visual acuity (BCVA) score worse than 55 ETDRS letters (20/80 Snellen
             equivalent).

          -  Chronic, recurrent or severe inflammatory eye disease.

          -  Ocular trauma within the preceding 6 months.

          -  Ocular infection or inflammation within the preceding 3 months.

          -  Clinically significant or progressive retinal disease.

          -  Other ocular pathology.

          -  Intraocular surgery within the 6 months prior to entry.

          -  Ocular laser surgery within the 3 months prior to entry.

          -  Any abnormality preventing reliable applanation tonometry.

          -  Any other conditions which would make the patient, in the opinion of the Investigator,
             unsuitable for the study.

          -  Recent use of high-dose (>1 gram daily) salicylate therapy.

          -  Recent, current, or anticipated treatment with any medication that augments adrenergic
             responses, or precludes use of an alpha-adrenergic agonist.

          -  Other protocol-specified exclusion criteria may apply.
Clinical trial NCT01095666 (phase 3, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, dapagliflozin, metformin, dapagliflozin placebo, pioglitazone
SMILES: CN(C)C(=N)NC(N)=N, CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O, CN(C)C(=N)NC(N)=N, N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females, 18 to 77 years old, with type 2 diabetes and with inadequate
             glycemic control

          -  Drug naive or treated with anti-diabetic medication for < 24 weeks

          -  C-peptide ≥ 1.0 ng/mL

          -  Body Mass Index ≤ 45.0 kg/m²

        Exclusion Criteria:

          -  AST and/or ALT > 3 times ULN

          -  Serum total bilirubin > 2 mg/dL

          -  Serum creatinine ≥ 1.50 mg/dL for men or ≥ 1.40 mg/dL for women

          -  Creatine kinase ≥ 3 times ULN

          -  Symptoms of severely uncontrolled diabetes

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases
Clinical trial NCT00135330 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: exenatide, rosiglitazone
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  HbA1c of 6.8% to 10.0%, inclusive.

          -  Body mass index (BMI) of 25 kg/m^2 to 40 kg/m^2, inclusive.

        Exclusion Criteria:

          -  Have participated in this study previously, or have received exenatide, pramlintide
             acetate, GLP-1 analogs, or dipeptidyl peptidase-IV (DPP-IV) inhibitors

          -  Have participated in an interventional, medical, surgical, or pharmaceutical study (a
             study in which an experimental, drug, medical, or surgical treatment was given) within
             30 days of study start. This criterion includes drugs that have not received
             regulatory approval for any indication at the time of study start.

          -  Treated with any of the following medications:

               -  Thiazolidinedione within 5 months of screening;

               -  Sulfonylurea within 3 months of screening;

               -  Metformin/sulfonylurea combination therapy within 3 months of screening;

               -  Alpha-glucosidase inhibitor within 3 months of screening;

               -  Meglitinide within 3 months of screening;

               -  Insulin for more than 1 week within the 3 months prior to screening.

               -  Symlin (pramlintide acetate) injection or Byetta (exenatide) injection at any
                  time

               -  Chronic (more than 2 weeks) or recent (within 4 weeks of study start) use of a
                  drug that directly affects gastrointestinal motility

               -  Are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid
                  therapy (excluding topical and inhaled preparations) or have received such
                  therapy within the 4 weeks immediately preceding study start

               -  Regular use of a medication with addictive potential such as an opiate, narcotic,
                  or tranquilizer

               -  Systemic antineoplastic agent

               -  Systemic transplantation medication

               -  Drugs for weight loss, including over-the-counter medications, within the 4
                  months prior to study start
Clinical trial NCT00299130 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: folate, methotrexate, methylprednisolone, placebo, rituximab
SMILES: NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion criteria:

          -  Adult patients 18-80 years of age.

          -  Rheumatoid arthritis (RA) for ≥ 6 months, diagnosed according to the revised 1987
             American College of Rheumatology (ACR) criteria for the classification of rheumatoid
             arthritis.

          -  Receiving outpatient treatment for RA.

          -  Swollen joint count (SJC) ≥ 8 (66 joint count), and tender joint count (TJC) ≥ 8 (68
             joint count) at screening and baseline.

          -  At screening, either

               -  C-reactive protein (CRP) ≥ 0.6 mg/dL (6 mg/L), or

               -  Erythrocyte sedimentation rate (ESR) ≥ 28 mm/hour.

          -  Inadequate response to methotrexate, having received and tolerated at a dose of 10-25
             mg/week it for ≥ 12 weeks.

        Exclusion criteria:

          -  Rheumatic autoimmune disease other than RA, or significant systemic involvement
             secondary to RA.

          -  Inflammatory joint disease other than RA, or other systemic autoimmune disorder.

          -  Diagnosis of juvenile rheumatoid arthritis, or RA before the age of 16.

          -  Surgery within 12 weeks of study or planned within 24 weeks of randomization.

          -  Previous treatment with any approved or investigational biological agent for RA, an
             anti-alpha4-integrin antibody or co-stimulation modulator, or cell-depleting therapy.
Clinical trial NCT00337779 (phase 3, status: completed)
Conditions: relapsing remitting multiple sclerosis
ICD codes: M94.1, A68.9, A68.0, A68.1, M35.6
Drugs: glatiramer acetate (ga) 40 mg, glatiramer acetate 20 mg
SMILES: CC(O)=O, CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          1. Diagnosis of confirmed and documented MS defined by the Revised McDonald criteria.

          2. Subjects must be of the relapsing-remitting (R-R) type.

          3. Subject has experienced prior to screening at least one documented relapse in 12
             months or at least 2 documented relapses in the 24 months or one documented relapse
             between 12 - 24 months with at least 1 documented T1-Gd enhancing lesion in the MRI
             performed 12 months prior screening.

          4. Disease duration for at least 6 months.

          5. Ambulatory with converted Kurtzke EDSS score of 0 - 5.

          6. Relapse free and stable neurological condition at least for 30 days prior screening.

          7. Age - 18-55 (inclusive)

        Exclusion Criteria:

          1. Previous use of Copaxone (glatiramer acetate)

          2. Treatment with corticosteroids within 30 days prior screening or between screening and
             baseline.

          3. Chronic corticosteroids treatment - more than 30 consecutive days.

          4. Subject with any clinically significant or unstable medical condition.

          5. Subjects participating in any other clinical trial (within 12 weeks prior to screening
             and thereafter).

          6. Known history of sensitivity to Gadolinium and inability to successfully undergo MRI
             scanning.
Clinical trial NCT00212771 (phase 3, status: completed)
Conditions: schizophrenia, schizoaffective disorder
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9, F25.9, F25.0, F25.1, F25.8
Drugs: asenapine, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subject with schizophrenia or schizoaffective disorder. Must have completed 12 months
             treatment under protocol 25517. Subject must sign a written informed consent.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable, clinically significant medical condition.
Clinical trial NCT01086384 (phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: fluticasone furoate/gw642444, fluticasone furoate
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Clinical diagnosis of asthma

          -  Reversibility FEV1 of twelve percent or greater and two hundred milliliters and
             greater approximately ten to forty minutes following two to four inhalations of
             albuterol

          -  FEV1 of fifty to ninety percent of predicted

          -  Currently using inhaled corticosteroid therapy

          -  History of one or more asthma exacerbations requiring treatment with oral/systemic
             corticosteroids or emergency department visit or in-patient hospitalization in
             previous year

        Exclusion Criteria:

          -  History of life threatening asthma in previous 5 years (requiring intubation, and/or
             associated with hypercapnia, hypoxic seizure or respiratory arrest

          -  Respiratory infection or oral candidiasis

          -  - Uncontrolled disease or clinical abnormality

          -  Allergies

          -  Taking another investigational medication or prohibited medication
Clinical trial NCT00219141 (phase 3, status: completed)
Conditions: hypertension, left ventricular hypertrophy, overweight
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10, I47.2, I49.01, I49.02, I49.3, Q21.0, I47.0, I50.1, E66.3
Drugs: aliskiren 150/300 mg, losartan 50/100 mg, aliskiren placebo, losartan 50/100 mg placebo
SMILES: COCCCOC1=C(OC)C=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=C1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with essential hypertension

          -  Patients with a BMI > 25 kg/m2

          -  Patients with LVH (LVWT ≥ 1.3 cm) confirmed by the ECHO

        Exclusion Criteria:

          -  Patients treated with an ACE or an ARB within 3 months of study entry (Study Visit 1)
             who are unable or unwilling to undergo the 3 month washout period.

          -  Patients treated with an ACE and ARB combination at study entry.

          -  Known secondary hypertension of any etiology (e.g., uncorrected renal artery
             stenosis).

        Other protocol related inclusion/exclusion criteria applied to the study.
Clinical trial NCT01529476 (phase 3, status: completed)
Conditions: pneumonia
ICD codes: A01.03, A02.22, A54.84, B01.2, B06.81, B77.81, J12.0
Drugs: levofloxacin, nemonoxacin
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, COC1=C2N(C=C(C(O)=O)C(=O)C2=CC=C1N1C[C@@H](C)C[C@H](N)C1)C1CC1
Eligibility criteria:

        Inclusion Criteria:

          1. Ages between 18 and 70;

          2. Weighs between 40 ~ 100 kg, and BMI ≥ 18 kg/m2;

          3. Must have a clinical diagnosis of CAP

          4. Chest X-ray shows new or persist/progressive infiltrates

          5. If female, non-lactating and at no risk or pregnancy (post-menopausal or must use
             adequate birth control)

          6. The patient is able to take the drug orally.

        Exclusion Criteria:

          1. Patients with CAP that, in the investigator's judgment, is severe enough to require
             hospitalization for intravenous antibiotic therapy and/or supplemental oxygen therapy
             with ICU support

          2. Known or suspected severe bronchiectasis, cystic fibrosis, active pulmonary
             tuberculosis or infection with other mycobacteria or fungi, known bronchial
             obstruction, a history of post-obstructive pneumonia, other confounding respiratory
             diseases, such as lung cancer, malignancy metastatic to the lungs, lung abscess,
             empyema, suspected aspiration pneumonia due to vomiting, or non-bacterial respiratory
             infection (chronic obstructive pulmonary disease [COPD] is not exclusionary)

          3. Clinically significant conduction or other abnormality on 12-lead ECG, or QTc interval

          4. Potassium is < 3.5 mmol/L

          5. Any known disease that seriously affect the immune system

          6. Active hepatitis or decompensated cirrhosis;

          7. Have used quinolones or fluoroquinolones within 14 days before enrollment

          8. Patients who are being or will be on a long-term medication of steroids